Daiichi, Merck pull HER3-DXd filing at FDA after confirmatory trial misses survival endpoint - Fierce Biotech
When Merck & Co. | After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in consecutive years.
Comments